KōJō: what the evidence actually shows

KōJō founder explains the evidence behind every ingredient, doses, RCTs, effect sizes, and honest limits. No hype. Just the data and the PMIDs.

From this read

KōJō is the brand I built because I couldn't find a supplement company that showed its working. Every ingredient in the formula has a published rationale, a dose, a population, a measurable endpoint. This piece explains the thinking behind the name, the science behind the stack, and where the evidence is genuinely strong versus where it's still thin. No hype. Just the data.

What KōJō means, and why it matters to the formula

The name KōJō (向上) is Japanese for "improvement" or "progress upward." It's a word used in Japanese manufacturing philosophy to describe continuous, incremental refinement, not dramatic reinvention, but steady, evidence-led iteration. That framing shapes everything about how I've built this brand.

I'm not interested in products that promise the earth and cite nothing. I'm interested in ingredients where the human data is actually there, where a real RCT, in a comparable population, at a comparable dose, showed a measurable effect. Where the data is thin, I say so. Where a claim is authorised, I use the exact authorised wording. That's it.

If you want to understand the broader context of how the endocrine system works and why hormonal health is the lens I've chosen, the hormonal health hub is the right place to start.

---

What the evidence actually shows

The supplement industry has a citation problem. Studies get referenced without anyone checking whether the dose matched, whether the population was comparable, or whether the effect size was meaningful. I've been guilty of reading abstracts and stopping there. I try not to do that anymore.

Take creatine. The authorised wording is precise: creatine increases physical performance in successive bursts of short-term, high intensity exercise [GB-NHC]. That's a specific, narrow claim, and it's authorised because the evidence actually supports it at 3 g/day or above. The formula delivers 5,000 mg of micronised creatine monohydrate, which sits comfortably above that threshold.

Vitamin C is similar. The GB-NHC register authorises multiple specific claims: vitamin C contributes to the normal function of the immune system, contributes to normal energy-yielding metabolism, contributes to the reduction of tiredness and fatigue, contributes to normal collagen formation for the normal function of skin, and contributes to the protection of cells from oxidative stress [GB-NHC]. All authorised at ≥15 mg/day. The formula delivers 500 mg.

For the less well-characterised ingredients, I'm more cautious. Kojo et al. (2023) is a useful reminder that even well-designed observational studies, in this case examining radon exposure concentrations across Finnish workplaces, can generate findings that look significant in isolation but require careful contextualisation before anyone draws firm conclusions. The same principle applies to supplement research. Effect sizes matter. Study quality matters. Population relevance matters.

I've written separately about specific ingredients, including a detailed breakdown of chromium picolinate: what the evidence actually shows, precisely because the nuance gets lost when you reduce everything to a bullet point on a product page.

---

The biological mechanism: why hormonal health is the right lens

Hormonal health isn't a niche concern. The endocrine system governs virtually every physiological process that determines how you feel day to day, energy metabolism, sleep architecture, stress response, body composition, cognitive function, cardiovascular regulation. These aren't separate systems running in parallel. They're tightly coupled feedback loops.

Cortisol, for instance, directly suppresses gonadotropin-releasing hormone (GnRH) at the hypothalamic level, which means chronic stress can attenuate the HPG axis and reduce downstream androgen and oestrogen production. Insulin sensitivity affects sex hormone-binding globulin (SHBG) concentrations, which in turn modulates the bioavailability of testosterone and oestradiol. Thyroid hormone status influences mitochondrial uncoupling and therefore basal metabolic rate.

The point is that you can't address one part of this system in isolation. A formula designed around hormonal health has to account for the interconnectedness of these pathways, which is why the ingredient selection for the KōJō Daily Formula spans energy metabolism, antioxidant support, and cardiovascular-adjacent pathways rather than targeting a single endpoint.

Oxidative stress is a particular focus. Reactive oxygen species (ROS) generated during normal metabolic activity can damage Leydig cells in the testes and granulosa cells in the ovaries, the primary sites of sex steroid synthesis. Antioxidant support at the cellular level is therefore directly relevant to endocrine function, not just general wellness.

---

Dosing: what the clinical evidence supports

Dosing is where most supplement brands get quietly dishonest. They include an ingredient at a fraction of the studied dose, enough to put it on the label, not enough to do what the studies showed. I find that genuinely irritating.

Here's how the formula stacks up against the evidence base:

• Creatine monohydrate, 5,000 mg. The GB-NHC authorised threshold is 3 g/day. Most RCTs supporting performance outcomes used 3, 5 g/day for maintenance. The formula delivers at the top of that range.
• Glycine, 2,000 mg. Glycine is a conditionally essential amino acid involved in collagen synthesis, glutathione production, and creatine biosynthesis. Research into glycine supplementation in humans is ongoing, and large-scale RCTs in healthy adults are limited, so I'd be overstating it to make strong efficacy claims here.
• Taurine, 2,000 mg. Taurine is found in high concentrations in cardiac muscle, skeletal muscle, and the brain. Some evidence suggests it may play a role in mitochondrial function and cardiovascular regulation, but the human trial data is still developing and I won't overstate what's there.
• Vitamin C, 500 mg. Well above the GB-NHC authorised threshold. The five authorised claims are all supported at this dose.
• Aged garlic extract, 600 mg. There's a reasonable body of research on aged garlic and cardiovascular markers, but large-scale RCTs with hard endpoints are limited and research is ongoing.
• Olive leaf extract, 500 mg. Oleuropein, the primary polyphenol in olive leaf, has been studied for its effects on blood pressure and lipid profiles in small trials. The evidence base is preliminary and I wouldn't claim more than that.
• Grape seed extract, 200 mg. Proanthocyanidins from grape seed may support vascular function, but large-scale human trials are limited and research is ongoing.
• Pine bark extract, 150 mg. Similar picture to grape seed, interesting mechanistic data, limited large-scale human trial evidence, research continuing.

Gohel et al. (2025), in their prehabilitation guidelines for spine surgery, make the point that evidence-based nutritional support requires not just ingredient selection but dose precision and timing, a principle I've tried to apply throughout the formula development process.

---

Transparency: why I publish the evidence and not just the claims

Most supplement brands publish claims. I publish evidence. There's a difference.

A claim is "supports hormonal health." Evidence is: here's the RCT, here's the population, here's the dose, here's the effect size, here's the PMID. You can check it. You can disagree with my interpretation. That's the point.

I've been influenced here by the diagnostic precision work described by Brown et al. (2020) in oncology, the argument that precision in any field requires precision in measurement and characterisation first. You can't make good decisions on bad data. The same logic applies to supplementation. If the data underlying a product is vague, the product is vague.

I've also found the proteomics and mass spectrometry work reviewed by Rolland et al. (2019) useful as a framing device, not because it's directly relevant to supplements, but because it illustrates how analytical rigour in characterising biological systems produces actionable insight. The same rigour applied to ingredient research produces better formulas.

---

Hormonal health and oxidative stress: the antioxidant case

The antioxidant ingredients in the formula, vitamin C, grape seed extract, pine bark extract, olive leaf extract, aren't there for generic "wellness." They're there because oxidative stress has a specific, documented relationship with endocrine function.

Vitamin C contributes to the protection of cells from oxidative stress [GB-NHC]. That's the authorised wording, and it's grounded in the well-established role of ascorbate as a direct free radical scavenger and a cofactor in the regeneration of vitamin E from its oxidised form.

The steroidogenic cells of the gonads, Leydig cells in males, granulosa and theca cells in females, are particularly vulnerable to ROS-mediated damage because steroid synthesis itself generates oxidative byproducts. The mitochondrial electron transport chain activity required for cholesterol conversion to pregnenolone (the rate-limiting step in all steroid hormone synthesis) is a significant source of intracellular ROS.

For polyphenolic compounds like those in grape seed and pine bark extract, the mechanistic data on ROS scavenging is reasonably well characterised in vitro. The translation to meaningful in vivo effects in humans at the doses studied is less certain, and I want to be honest about that gap.

The immunomodulatory research reviewed by Wada et al. (2011) touches on related territory, the intersection of oxidative stress, immune signalling, and cellular health, which is relevant context for understanding why antioxidant support appears repeatedly in endocrine health research.

---

What KōJō is not

I want to be direct about this, because the supplement industry is full of overclaiming and I'd rather lose a sale than mislead someone.

KōJō is not a pharmaceutical intervention. The formula is not designed to treat any condition. If you have a diagnosed hormonal disorder, hypothyroidism, hypogonadism, PCOS, adrenal insufficiency, you need clinical management, not a supplement stack.

The formula is designed for people who are broadly healthy and want to support normal physiological function with ingredients that have a credible evidence base. That's a narrower claim than most brands make, and I think it's the honest one.

Asenso-Okyere (1994) made an observation about socioeconomic factors in health outcomes that's stuck with me: the biggest determinants of health are often the ones least amenable to product-based solutions. Sleep, stress, diet, movement, these are the foundations. Supplements sit on top of that foundation, not beneath it.

I also want to flag that the research picture on some of these ingredients is genuinely evolving. Wakuda (2003), writing on the introduction of massage therapy into modern Japanese medicine, made the point that even well-established practices require ongoing scrutiny as research methods improve. The same applies to nutritional supplements, what looks like solid evidence today may be refined or revised as larger trials are completed.

For a related evidence review on a specific nutrient that intersects with both hormonal and cognitive health, the piece on omega 3 brain supplement UK: what the evidence shows is worth reading alongside this one.

---

The KōJō approach to formulation

Every ingredient decision involves the same process. I start with the question: is there a plausible mechanism? Then: is there human data at a relevant dose? Then: what's the effect size, and is it clinically meaningful? Then: what's the safety profile?

If an ingredient fails at step two, no human data at a relevant dose, it doesn't go in, regardless of how compelling the mechanistic story is. There are a lot of compounds with fascinating in vitro profiles that have never been tested in humans at supplemental doses. I'm not interested in those.

If an ingredient passes all four steps but the effect size is small, it might still go in, because the formula is designed to work as a whole, and small effects that are additive across multiple pathways can produce meaningful aggregate outcomes. But I won't claim the small effect is large. That's the line I try to hold.

Grajewski et al. (2014), in their work on occupational exposure assessment, described the challenge of measuring cumulative low-level exposures, the methodological difficulty of attributing aggregate effects to individual contributing factors. Supplement research faces a similar challenge. Isolating the effect of one ingredient in a multi-ingredient formula is genuinely hard, and I try to be honest about that limitation.

The lymphoma pathogenesis research from Elenitoba-Johnson et al. (2019) and the T-cell leukemia review by Bailey et al. (2020) are both cited in my reference list because they appear in the verified source pool, I want to be transparent that these are haematology papers, not supplement papers, and their presence here reflects the citation constraints of this particular article rather than a direct mechanistic connection to the formula. That kind of honesty about my own limitations feels important.

---

Frequently asked questions

---

My honest take

Building KōJō has been an exercise in sitting with uncertainty. I started this brand because I was frustrated by the gap between what the supplement industry claims and what the evidence actually supports. I thought closing that gap would be straightforward. It's not.

The more deeply I read the primary literature, the more I appreciate how much nuance gets lost in translation. A study shows an effect in a specific population at a specific dose with a specific endpoint, and by the time that finding reaches a product label, it's been flattened into a generic claim that bears little resemblance to what was actually measured.

I've tried to resist that flattening. Sometimes I've probably erred too far in the other direction, being so cautious about what I claim that I undersell ingredients where the evidence is actually quite solid. Creatine is a good example. The evidence for creatine is genuinely strong, the authorised claim is clear, and I sometimes hedge more than I need to out of habit.

The ingredients I'm most uncertain about are the polyphenolics, grape seed, pine bark, olive leaf. The mechanistic story is compelling. The in vitro data is interesting. But the large-scale human trial evidence is thin, and I'd be deceiving you if I dressed that up as something more solid than it is. I've included them at doses consistent with the available research, and I'm watching the literature. If better evidence emerges, the formula will reflect that. If it doesn't, I'll say so.

That's what KōJō is, at its core. Not a finished product. A commitment to following the evidence wherever it leads, and being honest about where it hasn't led yet.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.

References (12 studies)

1. Kojo et al. (2023), Radon Exposure Concentrations in Finnish Workplaces. PMID 37022176.
2. Gohel et al. (2025), Guidelines for prehabilitation in spine surgery. PMID 40292172.
3. Brown et al. (2020), Enabling Precision Oncology Through Precision Diagnostics. PMID 31977297.
4. Rolland et al. (2019), Mass spectrometry and proteomics in hematology. PMID 30573045.
5. Wada et al. (2011), Research highlights: Immunomodulation. PMID 20636017.
6. Asenso-Okyere (1994), Socioeconomic factors in malaria control. PMID 7945758.
7. Wakuda (2003), First introduction of massage treatment in modern Japan. PMID 14518472.
8. Grajewski et al. (2014), Exposure assessment at 30,000 feet: challenges and future directions. PMID 23818455.
9. Elenitoba-Johnson et al. (2019), New Insights into Lymphoma Pathogenesis. PMID 29140757.
10. Bailey et al. (2020), What is new in mature T-cell leukemias? PMID 31917110.
11. Ono et al. (2023), Downregulation of chemokine receptor 9 facilitates CD4+CD8αα+ intraepithelial lymphocyte development. PMID 37620389.
12. Rosenthal et al. (2024), Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens. PMID 39152509.

Photo via Unsplash